
Opinion|Videos|July 24, 2024
Long-Term Follow-Up from CheckMate 9LA at ASCO 2024
Author(s)Jason Porter, MD
A key opinion leader examines the overall survival data from the CheckMate 9LA study, which evaluated nivolumab plus ipilimumab plus chemotherapy in metastatic non-small cell lung cancer patients, and explores how the long-term follow-up results inform treatment decisions in this setting.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Discuss the data that was presented at the ASCO 2024 on overall survival from the
CheckMate 9LA study with the use of nivolumab + ipilimumab + chemotherapy in patients with metastatic NSCLC. - What are your key takeaways from this study?
- How do you think the long term follow up data supports decision-making in metastatic NSCLC?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
2
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
3
Digital, Blood-Based Innovations Transform Alzheimer Disease Detection: Ken Cohen, MD, FACP
4
Revumenib Granted FDA Approval for R/R NPM1-Mutated AML
5
















































